

Provided by:



## **Melanoma and Cutaneous Malignancy Tumor Board 2023-2024**

**Melanoma and Cutaneous Malignancy Tumor Board 2023-2024 - 12/6/2023**

**December 6, 2023**

**12:00 PM - 1:00 PM**

**PCAM South Tower Room 10-124**

### **Target Audience**

This program has been designed for Dermatology, Internal Medicine - Medical Oncology, Pathology - Clinical, Radiation Oncology, Otolaryngology, Dermatology - Dermatopathology, Pathology - Anatomic, Obstetrics And Gynecology - Gynecologic Oncology, Pathology - Dermatopathology, Internal Medicine - Hospice And Palliative Medicine, Surgery - Complex General Surgical Oncology

### **Series Educational Objectives**

After participating in this regularly scheduled series, participants should be able to:

- 1 Discuss a multidisciplinary approach to care for patients with melanoma and other malignant skin diseases
- 2 Discuss how to provide a plan for accurate diagnosis, complete staging, and proper treatment for patients.
- 3 Describe how to treat and manage patients with melanoma and other cutaneous malignancies using both proven standardized methods and consider current investigative clinical trials.

### **Accreditation**

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For more information, please contact

**Ahron Flowers, Nyree Harper**

**(215) 360-0911, (215) 662-3002**

**[aflow@pennmedicine.upenn.edu](mailto:aflow@pennmedicine.upenn.edu), [Nyree.Harper@Pennmedicine.upenn.edu](mailto:Nyree.Harper@Pennmedicine.upenn.edu)**

**Check your transcript online at <https://upenn.cloud-cme.com>**

## Designation of Credit

**Physicians:** Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**ABIM MOC:** up to 1 MOC points

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

**ABPath MOC:** up to 1 MOC points

This activity has been registered to offer credit toward the American Board of Pathology's (ABPath) Continuing Certification program. Physicians can earn up to 1.00 Lifelong Learning credits through ABPath.

**Nurses:** This activity is for 1.00 contact hours.

**Pharmacists:** This activity is not approved for pharmacy contact hours

**PAs:** Penn Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria.

This activity is designated for 1.00 AAPA Category 1 CME credit(s). PAs should only claim credit commensurate with the extent of their participation.

**Approved for (PSRM) patient safety/risk management designation**

**Acknowledgement of Commercial Support\***

None

### Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships that they have with any commercial interest that provide products or services that may be relevant to the content of this continuing education activity. For this purpose, we consider relationships of the person involved to include financial relationships of a spouse or partner.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are based on valid content, and are independent of control from commercial interests and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain relationships that created a conflict of interest relevant to the topic of their presentation. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no relevant financial relationships with any commercial interests related to the content of this educational activity. Any peer reviewer with a potential conflict of interest will recuse themselves from the peer review process.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Michael Farwell, MD	Other Planning Committee Member	Grant or research support-Merck & Co Grant or research support-Bristol-Myers Squibb Grant or research support-ImaginAb Grant or research support-Carisma - 05/25/2023
Lynn M Schuchter, MD	Course Director, Faculty	Nothing to disclose - 09/12/2023
Ravi Amaravadi, MD	Other Planning Committee Member	Ownership-Pinpoint Therapeutics   Advisor-Tasca   Advisor-Deciphera   Grant or research support-Novartis (Relationship has ended)  Grant or research support-Deciphera  Grant or research support-Springworks Grant or research support-Merck & Co  Grant or research support-Bristol-Myers Squibb  Grant or research support-Pinpoint Therapeutics  Advisor-Immunacell - 11/06/2023
Kristin Kreider, PA-C	Physician Assistant Planner	Nothing to disclose - 02/21/2023
Giorgos Karakousis	Other Planning Committee Member	Advisor-Merck & Co (Relationship has ended)  Grant or research support-Merck & Co - 11/02/2023
Tara C Mitchell, MD	Co-Director	Honoraria-Merck & Co  Honoraria-Bristol-Myers Squibb  Honoraria-Pliant Therapeutics (Relationship has ended)  Honoraria-Pfizer

		(Relationship has ended)  Honoraria-GigaGen (Relationship has ended) - 10/06/2023
Suzanne McGettigan	Nurse Planner	Speakers Bureau-Bristol-Myers Squibb Speakers Bureau-Merck & Co Consulting Fee-Pfizer, Inc. Speakers Bureau-Regeneron Pharmaceuticals, Inc. - 10/26/2023
John N Lukens, MD	Other Planning Committee Member	Nothing to disclose - 02/24/2023
Joanna Walker, MD	Other Planning Committee Member	Nothing to disclose - 11/05/2023
Eric Morgan, MD	Other Planning Committee Member	Nothing to disclose - 08/30/2023

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected